Full Text
Cost-Effectiveness Analysis of Regorafenib for Third-Line Metastatic Colorectal Cancer (MCRC) Compared to Cetuximab Plus Irinotecan in China

Abstract

Authors

J Liu S Zhu W Sun L Tao D Xiao J Xuan

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×